Clinical Trials Browser

Phase 2 × repotrectinib × 1 year × Clear all

NCT06315010 2026-02-25

REPOSE

Phase 2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06408168 2026-01-05

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Phase 2 Terminated

Carcinoma, Lobular